ライフサイエンスコーパス: effector T-cell

1 mation (e.g., IFN-gamma production by CD4(+) effector T cells).

2 antigen, despite increased numbers of CD8(+) effector T cells.

3 inducing regulatory T cells, and inhibiting effector T cells.

4 nction through CD39/CD73 pathway to regulate effector T cells.

5 d-brain barrier and a large influx of CD8(+) effector T cells.

6 eg frequency and by an increase in activated effector T cells.

7 elates with RICD sensitivity in human CD8(+) effector T cells.

8 ntly enhanced the activation of the incoming effector T cells.

9 sentation module, promoted the generation of effector T cells.

10 expansion, and differentiation of memory and effector T cells.

11 r the function of these different subsets of effector T cells.

12 e overexpressed, were capable of suppressing effector T cells.

13 t differed transcriptionally from memory and effector T cells.

14 Foxp3(+)Treg-induction does not trigger any effector T cells.

15 d crescentic GN and colocalize with CXCR3(+) effector T cells.

16 alpha and TIGIT and can efficiently suppress effector T cells.

17 ffector cytokines by Th1, Th2, Th17, and CD8 effector T cells.

18 for BTN3A1-dependent lysis by Vgamma9Vdelta2 effector T cells.

19 creased expansion and survival of pathogenic effector T cells.

20 jection or rejection mediated by transferred effector T cells.

21 ell as in a marked increase in cell death of effector T cells.

22 receptor, CXCR3, is upregulated on alopecic effector T cells.

23 despite being infiltrated by tumour-specific effector T cells.

24 or-1 (S1PR1) gene specifically in endogenous effector T cells.

25 ning more-differentiated effector memory and effector T cells.

26 to assess expression of selectin ligands by effector T cells.

27 sthma, which is driven by the priming of Th2 effector T cells.

28 nce development of MVO through the action of effector T cells.

29 ivity of DN T cells toward allogeneic CD4(+) effector T cells.

30 ion without inducing depletion of peripheral effector T cells.

31 ate ELS development in RA through control of effector T cells.

32 induction of anergy in CHIKV-specific CD4(+) effector T cells.

33 vity and hapten-specific IFN-gamma-producing effector T cells.

34 by a process that seems to be driven by CD8 effector T cells.

35 at affect the balance between regulatory and effector T cells.

36 ent conjugate formation in primary naive and effector T cells.

37 promoted bacterial persistence by inhibiting effector T cells.

38 ent with their co-localization with T-bet(+) effector T cells.

39 or signaling and regulating the migration of effector T cells.

40 cells arise from a subset of fate-permissive effector T cells.

41 in adult mice restricted to rapidly dividing effector T cells.

42 epigenetic silencing of pro-memory genes in effector T cells.

43 inhibitors of T-bet function in CD4 and CD8 effector T cells.

44 ding IL-13(+)IL-17(+)CD4(+) double-producing effector T cells.

45 apoptosis and inhibiting expansion of donor effector T cells.

46 expression of gut-homing molecules on those effector T-cells.

47 , and suppressed proliferation of allogeneic effector T-cells.

48 jection of transplanted organs by activated (effector) T cells.

49 f CD8(+) central memory T cells and terminal effector T cells, a decrease in the coexpression of inhi

50 er model of colitis, as evidenced by reduced effector T cell accumulation, systemic production of inf

51 ue PMN as a potential key factor in aberrant effector T cell activation and initiation of immune-driv

52 Effector T cell activation coincided with a reduction in

53 e gammadeltaT cells as central regulators of effector T cell activation in cancer via novel cross-tal

54 y during bacterial infections by controlling effector T cell activation.

55 that systemic activation of NRF2 suppresses effector T cell activities independently of Tregs and th

56 CD9(+) Bregs controls the expansion of lung effector T cells allowing the establishment of a favorab

57 2 and 3 are antagonists of T-bet function in effector T cells and are important for the control of in

58 le of intestinal Tr1 cells in the control of effector T cells and development of diabetes.

59 e transcriptional programs characteristic of effector T cells and drove transitioning as well as esta

60 interaction upregulated CD40L expression on effector T cells and enhanced T cell proliferation and I

61 ocyte subpopulation essential for curtailing effector T cells and establishing peripheral tolerance.

62 Effector T cells and fibroblasts are major components in

63 on inevitably incurs differentiation towards effector T cells and impairs persistence following adopt

64 ls that an oncolytic vaccinia virus attracts effector T cells and induces PD-L1 expression on both ca

65 by accumulation of parasite-specific CD8(+) effector T cells and infected red blood cells in the bra

66 ne C3ar1/C5ar1 signaling causes expansion of effector T cells and instability of regulatory T cells a

67 activation of cytotoxic EBV-specific CD4(+) effector T cells and killing of infected B cells.

68 dispensable for generating cytotoxic CD8(+) effector T cells and maintaining memory CD8(+) T cell po

69 ating lymphopenia and a higher percentage of effector T cells and natural killer (NK) cells present i

70 Cs) and, consequently, negative selection of effector T cells and positive selection of regulatory T

71 d activates APCs, efficiently induces CD4(+) effector T cells and primes for enhanced infant response

72 eted quantitative and qualitative changes in effector T cells and prolonged preservation of endogenou

73 The involvement of effector T cells and regulatory T (T reg) cells in oppos

74 We analyzed CD4(+) effector T cells and regulatory T cells (Tregs) from per

75 semination and host morbidity by controlling effector T cells and the associated downstream hyperacti

76 flammatory diseases through the expansion of effector T cells and the induction of proinflammatory cy

77 role for NIK in mediating the generation of effector T cells and their recall responses to antigens.

78 aled minimal overlap in TCR sequence between effector T cells and Tregs in the CNS.

79 vascular inflammation, enriched for PD-1(+) effector T cells, and amplified tissue production of mul

80 e IL-2 receptor alpha chain, CD45RO(+)CD4(+) effector T cells, and autoantibodies, and this was predi

81 ncies of gammadelta T cells, CD44(+)CD62L(-) effector T cells, and Foxp3(+) regulatory T cells were e

82 T cells, decrease production of IFNgamma by effector T cells, and prevent early and increase late IL

83 timuli and promotes immune tolerance through effector T-cell anergy and enhanced Treg function.

84 Whereas effector T cells are found in the brain parenchyma where

85 vel, how it impacts cytokine production when effector T cells are restimulated is unknown.

86 during M. tuberculosis infection, activated effector T cells are the major source accounting for IL-

87 te into chronic infection than do functional effector T cells arising early in acute infection.

88 milar profile in mediating Ca(2+) release in effector T cells as in their counterpart naive T cells a

89 anti-TIM-3 treatment promotes generation of effector T cells as shown by acquisition of an activated

90 ailable regarding the cytokine repertoire of effector T cells associated with peanut allergy, and how

91 lii-induced exhaustion shows upregulation of effector T cell-associated genes in the absence of NFAT1

92 ry lymphoid structures and actively restrain effector T cells at the tumor site.

93 Targeting cancer through the use of effector T cells bearing chimeric Ag receptors (CARs) le

94 f circulating gluten-specific Treg cells and effector T cells both increased significantly after oral

95 accination is a promising strategy to induce effector T cells but also regulatory Foxp3(+) CD25(+) CD

96 unction of in vitro-established Th1 and Th17 effector T cells but also significantly dampened ex vivo

97 V-associated adaptive NK cells and cytotoxic effector T cells but differed from those of canonical NK

98 dies that redirect the cytotoxic activity of effector T cells by binding to CD3, the signaling compon

99 tion of regulatory T cells (Treg) and dampen effector T cells can be effective to limit stromal kerat

100 The ratio between T reg and effector T cells can therefore determine the outcome of

101 e state was transient and functioned only in effector T cells capable of aerobic glycolysis.

102 ion can cause Tregs to de-differentiate into effector T cells capable of producing proinflammatory cy

103 nflammatory profile, through recovery of the effector T cells (CD4(+)T-bet(+) and CD8(+)T-bet(+)), as

104 IY-I2-BODIPY treated mice had high levels of effector T-cells compared to controls.

105 the liver and spleen, and greater numbers of effector T cells, cytokine-secreting T cells, and prolif

106 5), as demonstrated by increased NK cell and effector T-cell cytolytic function, reduced T-cell PD-1

107 Arteries infiltrated by PD-1(+) effector T cells developed microvascular neoangiogenesis

108 After pathogen clearance, most effector T cells die, and only a small number of memory

109 x1-d impacts lupus development by regulating effector T cell differentiation and promoting TFHs at th

110 chanism by which aerobic glycolysis promotes effector T cell differentiation and suggest that LDHA ma

111 ng regulatory T cell generation, restraining effector T cell differentiation, and potentiating memory

112 ls the metabolic reprogramming that supports effector T cell differentiation.

113 le or repeated exposure to antigen, delaying effector T-cell differentiation and exhaustion.

114 V tet(low) and tet(high) CTLs are functional effector T cells differing by proliferation, numbers in

115 upled to production of differentiated CD4(+) effector T cells during clonal selection.

116 turation and uncover a role for low-affinity effector T cells during early microbial containment.

117 hanisms that regulate the complex process of effector T-cell egress from the dLN after infection are

118 Viral clearance requires effector T-cell egress from the draining lymph node (dLN

119 l intrinsic S1PR1 is the master regulator of effector T-cell emigration from the dLN.

120 Effector T cells equipped with engineered antigen recept

121 okine therapy to eliminate tumors may target effector T cells, even outside of TCR specificity, as lo

122 D) regulates immune responses by restraining effector T cell expansion and limiting nonspecific damag

123 egative regulatory programs, which constrain effector T cell expansion and prevent increasing oligocl

124 iatic Mo-MDSCs prevent proper suppression of effector T-cell expansion and hamper the immune system's

125 eased de novo Treg-cell numbers and dampened effector T-cell expansion and IFN-gamma production.

126 Rag2(-/-) mice receiving NLRX1(-/-) naive or effector T cells experienced increased disease activity

127 and myeloid-derived suppressor cells, while effector T cells expressed more intracellular IFNgamma i

128 8(+) T cells, there is an increase of CD8(+) effector T cells expressing the stimulatory receptor Klr

129 sis reveals that miR-125a suppresses several effector T-cell factors including Stat3, Ifng and Il13.

130 However, in contrast to WT, S1PR1(-/-) effector T cells failed to enter the sinuses.

131 eoplasms, antigen-presenting cells (APC) and effector T cells form transcellular molecular complexes.

132 is MGL1-dependent as shown by reduced CD8(+) effector T cell frequencies in MGL1-deficient mice.

133 tionality as controls but may require higher effector T-cell frequencies to ensure pathogen control.

134 Dysbiosis suppresses trafficking of effector T cells from the gut to the leptomeninges after

135 become immune resistant through exclusion of effector T cells from the tumor microenvironment is not

136 re are increased levels of apoptosis seen in effector T cells from tuberculosis patients.

137 to type I interferons, which interfered with effector T cell function and increased the expression of

138 latory pathways play key roles in regulating effector T cell function and responses to anti-PD-L1/PD-

139 pression of this miRNA family confers proper effector T cell function at both physiological and patho

140 kin 6 (IL-6) from epithelial cells, tailored effector T cell function, promoting increases in gingiva

141 ctor 4), a critical transcription factor for effector T cell function.

142 reased energetic and biosynthetic demands of effector T cell function.

143 We previously reported that donor effector T-cell function and graft-versus-host disease (

144 evidence that altered myelopoiesis, reduced effector T-cell function, and expansion of immature myel

145 t can be therapeutically targeted to restore effector T-cell function.

146 t prevents DCs from prolonging excessive Th1 effector T cell functions and autoimmunity.

147 e efficacy of therapeutic Treg subversion of effector T cell functions at the site of inflammation to

148 already unable to match the bioenergetics of effector T cells generated during acute infection.

149 the notion of an extrafollicular pathway for effector T cell generation.

150 us, enrichment for phosphoantigen-responsive effector T cells has occurred within the fetus before po

151 Effector T cells have the capability of recognizing and

152 , Th9 and Th17 cells are conventional CD4(+) effector T cells identified as secretors of prototypical

153 sease phenotypes are not driven by miR-27 in effector T cells in a cell-autonomous manner.

154 nimmune" modality for intratumoral T reg and effector T cells in promoting tumor growth through the p

155 mined lysis mediated by human Vgamma9Vdelta2 effector T cells in response to the naturally occurring

156 is was associated with an increase in BM CD8 effector T cells in RIC mice and elevated blood and BM p

157 g long-term survival and maintenance of CD4+ effector T cells in target organs.

158 T cells, and expansion of subpopulations of effector T cells in the blood.

159 ls (Tregs) and reduction of encephalitogenic effector T cells in the central nervous system.

160 here is an elevated prevalence of pathogenic effector T cells in the glands with a sexually dimorphic

161 s and form stable, cognate interactions with effector T cells in the graft.

162 Treg cells lost their ability to suppress effector T cells in the presence of IL-33.

163 altered balance of resident Tregs and CD4(+) effector T cells in the skin and overreactive inflammato

164 This resulted in increased numbers of effector T cells in the tumor, and T cell depletion abol

165 iciency reduces the generation of gut-homing effector T-cells in both mesenteric lymph nodes and Peye

166 SCFA also suppressed effector T cell induction in the CLN and mesenteric lymp

167 ests that the balance between regulatory and effector T cells influences human HSV-2 disease.

168 athways govern the differentiation of CD8(+) effector T cells into memory or exhausted T cells during

169 ital imaging indicated failed trafficking of effector T cells into tumors.

170 etween FOXP3+ regulatory T cells (Tregs) and effector T cells is a likely contributing factor in the

171 aerobic glycolytic preference in NLRX1(-/-) effector T cells is combined with a decreased sensitivit

172 Improving the functional avidity of effector T cells is critical in overcoming inhibitory fa

173 ver, accumulation of donor CD4(+) and CD8(+) effector T cells is increased in CD70(-/-) versus wild-t

174 ression of these factors in Treg cells-as in effector T cells-is indicative of heterogeneity of funct

175 The early release of low-affinity effector T cells led to rapid target cell elimination ou

176 on of instable Treg cells and acquisition of effector T-cell-like function.

177 Ectopic expression of miR-17 imparted effector-T-cell-like characteristics to Treg cells via t

178 as the differentiation and function of other effector T cell lineages.

179 Early after infection, WT and S1PR1(-/-) effector T cells localized exclusively within the paraco

180 Vgamma9Vdelta2 effector T cells lyse cells in response to phosphorus-co

181 ated that IC3 expressed higher levels of the effector T cell markers than TC3, suggesting that PD-L1

182 -deficient Treg cells efficiently suppressed effector T cell-mediated graft-versus-host disease after

183 Here we report plasticity in effector T cell metabolism in response to changing nutri

184 Specifically, as the effector T cells metabolized glucose and consumed O2, th

185 Effector T cell migration into inflamed sites greatly ex

186 Effector T cell migration through tissues can enable con

187 , we visualized endogenous pathogen-specific effector T-cell migration within, and from, the dLN.

188 ults suggest that, in polarized autoreactive effector T cells, miRNA synthesis is inhibited in respon

189 T cells are activated and differentiate into effector T cells, most of which undergo contraction afte

190 inhibit generation of early memory precursor effector T cells (MPEC).

191 in T cell immune responsiveness or T reg and effector T cell numbers.

192 resence of memory T cells in both twins, but effector T cells only in the ALS twin.

193 he production, expansion, and persistence of effector T cells over CD4Tregs and were associated with

194 D-1(hi) expressed on CD4(+) CD25(+) CD127(+) effector T cells (P < 0.001).

195 =0.015, n=9), and IFNgamma secretion by CD4+ effector T cells (p=0.026, n=10).

196 sures identifies Mtb-specific frequencies of effector T cell phenotypes at various time points post i

197 s T cell exhaustion state towards memory and effector T cell phenotypes.

198 Central nervous system (CNS)-infiltrating effector T cells play critical roles in the development

199 requencies of IFN-gamma and IL-17A-producing effector T cell populations in female SjS(S) mice compar

200 Treg subsets suppress effector T cell populations through the secretion of imm

201 memory T cell, and terminally differentiated effector T cell populations to the CD3 and CD28-activate

202 s experienced increased disease activity and effector T cell populations, whereas no differences were

203 be another mechanism by which Tregs suppress effector T cell populations.

204 induced partial clonal deletion and impaired effector T cell potential but enhanced regulatory T cell

205 Memory T cells sustain effector T-cell production while self-renewing in reacti

206 MPO-specific CD4(+) effector T cell proliferation was enhanced by co-culture

207 d by measuring the suppression of autologous effector T-cell proliferation by Treg cell in coculture.

208 DCs and T cells, diminished accumulation of effector T cells, promoted expression of exhaustion and

209 03), but negatively correlated with PD-1(hi) effector T cells (r = -0.22, P = 0.031).

210 emerge over time during AIG occurrence, the effector T cells rapidly become less susceptible to Treg

211 ablishment of a favorable regulatory T cells/effector T cells ratio in lungs.

212 Memory/effector T cells recirculate through extralymphoid tissu

213 moral Batf3 dendritic cells are critical for effector T cell recruitment.

214 CTLA4 expression on regulatory or effector T cells reduces T cell activation.

215 we demonstrate that CD39 expression on CD4(+)effector T cells represents a novel Th17 marker in the i

216 i leads to a Th1-polarized parasite-specific effector T cell response in the brain.

217 erozygous mice have a regulatory rather than effector T-cell response at the site of autoimmunity, su

218 Although the effector T-cell response in patients with celiac disease

219 cell plasticity to create flexibility in the effector T-cell response.

220 ritic cells, which results in suppression of effector T cell responses and protection of beta cells.

221 While early effector T cell responses are required for limiting para

222 H. pylori loads in the stomach by modulating effector T cell responses at the gastric mucosa.

223 -6 is an inflammatory cytokine that controls effector T cell responses but the mechanisms by which it

224 ve shown that elite controllers with minimal effector T cell responses harbor a low-frequency, readil

225 cells and has been implicated in augmenting effector T cell responses, including expression of the p

226 rom tumor-bearing mice were able to suppress effector T cell responses.

227 maturation and the subsequent development of effector T cell responses.

228 itory receptor expression on T cells dampens effector T cell responses.

229 nal characteristics of tolDCs and subsequent effector T cell responses.

230 At the cellular level, leptin promoted effector T-cell responses and facilitated the presentati

231 ong the most effective agents in controlling effector T-cell responses in humans.

232 /NFIL3 signalling axis as a key regulator of effector T-cell responses via induction of Tim-3, IL-10

233 ns, individuals with Down syndrome can mount effector T-cell responses with similar phenotype and fun

234 ction and as a redox-dependent checkpoint of effector T-cell responses.

235 red by re-engagement of the TCR on a cycling effector T cell, resulting in apoptosis.

236 Suppressor assays with activated effector T cells revealed that CD4(+) regulatory T cells

237 ic activity or glucose availability rendered effector T cells significantly less sensitive to RICD.

238 Most of these are short-lived effector T cells (SLECs) that die after clearance of the

239 suggest that DMF acts on specific memory and effector T cell subsets by limiting their survival, prol

240 ells (Tregs) uptake FA at a higher rate than effector T cell subsets, supporting the role of FA metab

241 constitute the entire spectrum of memory and effector T cell subsets.

242 all the phenotypic characteristics of memory-effector T cells such that with acute inactivation of th

243 pacities to suppress IFN-gamma production by effector T cells, suggesting that IL-33 not only favors

244 CARs) for the generation of antigen-specific effector T cells suggests that a similar approach could

245 integrates Treg cell activity and increased effector T cell survival into an efficient CD4(+) T cell

246 cells into functionally distinct subsets of effector T cells (T helper 1 (TH1), TH2, and TH17) defin

247 CD4+ effector T cell (Teff) (Th1 and Th17) and Treg subsets a

248 FAS inhibition during priming increased effector T cell (Teff) proliferation and strongly decrea

249 eg depletion and to a large degree on CD4(+) effector T cell (Teff) responses, was impaired with ICOS

250 CD4(+) effector T cells (Teff cells) and regulatory T cells (Tr

251 zed the translatome of virus-specific CD8(+) effector T cells (Teff cells) during acute infection of

252 Frequencies of effector T cells (Teff) and graft infiltrating immune ce

253 an epigenetic profile distinct from that of effector T cells (TEFF) and TMEM cells that was minimall

254 Effector T cells (TEFF) are a barrier to booster vaccina

255 interferon-gamma production by CD4(+)CD25(-) effector T cells (Teff).

256 feration of Foxp3(+) Tregs, but not Foxp3(-) effector T-cells (Teff), when CD4(+) T-cells are co-cult

257 imulation which also causes proliferation of effector T-cells (Teff).

258 rylation (OXPHOS) for energy production, and effector T cells (Teffs) rely on glycolysis for prolifer

259 rol iNKT cells suppress the proliferation of effector T cells (Teffs) through a cell contact-independ

260 ing infection and regulate autoreactive CD4+ effector T cells (Teffs) to prevent autoimmune diseases,

261 FR2 was also up-regulated on CD4(+) Foxp3(-) effector T cells (Teffs) upon TCR stimulation.

262 requencies of interferon gamma (IFNgamma)(+) effector T cells (Teffs), as well as allosensitization i

263 A4 in females correlated with an increase in effector T cells (Th1 and Th17), a decrease in regulator

264 hows that CCR5Teff cells are more similar to effector T cells than to regulatory T cells.

265 ection, activated naive T cells give rise to effector T cells that clear the pathogen and memory T ce

266 Alloreactive effector T cells that expanded in the absence of IL-6 we

267 reased intrinsic survival of multifunctional effector T cells that had downregulated PD-1 as well as

268 ntly observed that PDPN is also expressed on effector T cells that infiltrate target tissues during a

269 asculitic lesions contain a diverse array of effector T cells that persist despite corticosteroid the

270 sponding to microbial pathogens give rise to effector T cells that provide acute defense and memory T

271 cells, but only mucosal vaccination induced effector T cells that rapidly seeded uterine mucosa with

272 ion of regulatory T cells and contraction of effector T cells, thereby favoring viral persistence.

273 specific Tregs and reducing pro-inflammatory effector T cells, these microparticles inhibited destruc

274 Thus, our work uncovers a mode of action for effector T cells: they abrogate stromal-mediated chemore

275 rentiation, has recently been connected with effector T cells, though its role is still not clear.

276 ory CD8 T cells are derived from a subset of effector T cells through a process of dedifferentiation.

277 nes downregulated the response of autologous effector T cells to IFX.

278 4-MU reduced HA accumulation, constrained effector T cells to nondestructive insulitis, and increa

279 uld be reprogrammed toward a higher ratio of effector T cells to regulatory CD4(+) T cells.

280 checkpoint signaling, and the relocation of effector T cells to the center of the granulomata.

281 recruitment of PD1(-) naive, but not PD1(+), effector T cells to the target tissue, leaving the cells

282 ute-phase proteins and an increased baseline effector T-cell-to-regulatory T-cell gene expression rat

283 o for the potential transition of pathogenic effector T cells toward a more tolerogenic phenotype.

284 CRK proteins were required for effector T cell trafficking into sites of inflammation,

285 determinants for T cell antitumor immunity, effector T cell trafficking to the tumor site, and respo

286 Due to their ability to suppress effector T cells, Tregs have been increasingly explored

287 atured by reductions in the total content of effector T cells, Tregs, and myeloid-derived suppressor

288 ulators removes the repression and increases effector T-cell tumour infiltration, slows down tumour p

289 with Ag, drives differentiation in favor of effector T cells via the activation of mTOR pathway.

290 Peanut-reactive effector T cells were analysed in conjunction with speci

291 notype and functionality of antigen-specific effector T cells were analyzed with flow cytometry after

292 Conventional effector T cells were collected from draining lymph node

293 , exhaustion, and apoptosis in the activated effector T cells were inevitable.

294 pression strategies that selectively inhibit effector T cells while preserving and even enhancing CD4

295 lls and clonal expansion of activated CD8(+) effector T cells with a CD4(dim) CD8(+) phenotype, both

296 Thus, activated effector T cells with elevated expression of rat nonclas

297 opulation of circulating and tissue-resident effector T cells with immune-regulatory properties.

298 geneic CAR T cells show initial expansion as effector T cells, with a higher peak but rapid deletion

299 Thus, chemotactic migration of effector T cells within peripheral tissue forms an impor

300 ecular mechanisms that regulate migration of effector T cells within the interstitial space of inflam